These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 28502768)

  • 1. Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.
    Solomon M; Muro S
    Adv Drug Deliv Rev; 2017 Sep; 118():109-134. PubMed ID: 28502768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in therapies for neurological lysosomal storage disorders.
    Ellison S; Parker H; Bigger B
    J Inherit Metab Dis; 2023 Sep; 46(5):874-905. PubMed ID: 37078180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Advanced Strategies for the Treatment of Lysosomal Diseases Affecting the Central Nervous System.
    Gigliobianco MR; Di Martino P; Deng S; Casadidio C; Censi R
    Curr Pharm Des; 2019; 25(17):1933-1950. PubMed ID: 31566121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.
    Papademetriou J; Garnacho C; Serrano D; Bhowmick T; Schuchman EH; Muro S
    J Inherit Metab Dis; 2013 May; 36(3):467-77. PubMed ID: 22968581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic approaches for lysosomal storage diseases: a patent update.
    Urbanelli L; Sagini K; Polidoro M; Brozzi A; Magini A; Emiliani C
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):91-109. PubMed ID: 23713988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme Replacement Therapy: A Review and Its Role in Treating Lysosomal Storage Diseases.
    Li M
    Pediatr Ann; 2018 May; 47(5):e191-e197. PubMed ID: 29750286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lyso-glycosphingolipids: presence and consequences.
    van Eijk M; Ferraz MJ; Boot RG; Aerts JMFG
    Essays Biochem; 2020 Sep; 64(3):565-578. PubMed ID: 32808655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders.
    Del Grosso A; Parlanti G; Mezzena R; Cecchini M
    Adv Drug Deliv Rev; 2022 Sep; 188():114464. PubMed ID: 35878795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.
    Baik AD; Calafati P; Zhang X; Aaron NA; Mehra A; Moller-Tank S; Miloscio L; Praggastis M; Giovannone N; Pan C; Tang Y; Bridges S; Mujica A; Barbounis P; Yanolatos J; Gale N; Li N; Kyratsous CA; Schoenherr CJ; Murphy AJ; Economides AN; Cygnar KD
    Mol Ther; 2021 Dec; 29(12):3512-3524. PubMed ID: 34400331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel treatments and future perspectives: outcomes of intrathecal drug delivery.
    Dickson PI
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S124-7. PubMed ID: 20040323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A polylysine-polyhistidine fusion peptide for lysosome-targeted protein delivery.
    Iwasaki T; Murakami N; Kawano T
    Biochem Biophys Res Commun; 2020 Dec; 533(4):905-912. PubMed ID: 33008588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The blood-brain barrier and neurodegenerative lysosomal storage diseases].
    Urayama A
    Brain Nerve; 2013 Feb; 65(2):153-63. PubMed ID: 23399673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the central nervous system in lysosomal storage diseases: Strategies to deliver therapeutics across the blood-brain barrier.
    Critchley BJ; Gaspar HB; Benedetti S
    Mol Ther; 2023 Mar; 31(3):657-675. PubMed ID: 36457248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme replacement therapy for lysosomal storage diseases.
    Lachmann RH
    Curr Opin Pediatr; 2011 Dec; 23(6):588-93. PubMed ID: 21946346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for lysosomal storage diseases.
    Ohashi T
    Pediatr Endocrinol Rev; 2012 Oct; 10 Suppl 1():26-34. PubMed ID: 23330243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New strategies for enzyme replacement therapy for lysosomal storage diseases.
    Grubb JH; Vogler C; Sly WS
    Rejuvenation Res; 2010; 13(2-3):229-36. PubMed ID: 20345279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysosomes as a therapeutic target.
    Bonam SR; Wang F; Muller S
    Nat Rev Drug Discov; 2019 Dec; 18(12):923-948. PubMed ID: 31477883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of Enzyme Drugs Derived from Transgenic Silkworms to Treat Lysosomal Diseases].
    Itoh K; Nishioka SI; Hidaka T; Tsuji D; Maita N
    Yakugaku Zasshi; 2018; 138(7):885-893. PubMed ID: 29962464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.